Breaking News
Get 50% Off 0
🧩 Based on my current watchlist, how should I diversify my portfolio?
Ask WarrenAI
Close

Celltrion Inc (068270)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
174,100 +1600    +0.93%
07:29:59 - Closed. Currency in KRW
Type:  Equity
Market:  South Korea
ISIN:  KR7068270008 
  • Volume: 345,483
  • Bid/Ask: 174,100 / 174,200
  • Day's Range: 171,700 - 174,500
Celltrion 174,100 +1600 +0.93%

Celltrion Inc Company Profile

 
Get an in-depth profile of Celltrion Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

2391

Equity Type

ORD

Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of various therapeutic proteins for the treatment of oncology diseases. It operates through Biopharmaceutical Medicines, Chemical Medicines, and Others segments. The company offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin’s lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. It is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. In addition, the company engages in the wholesale/retail of medicines. The company distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.

Contact Information

Address 23, Academy-ro Yeonsu-gu
Incheon,
South Korea
Phone 82 3 2850 5000
Fax -

Top Executives

Name Age Since Title
Wonkyung Choi - 2023 Independent Director
Jung-Jin Seo 68 2002 Inside Co-Chairman of the Board
Hyong-Gi Kim 60 2014 CEO & Internal Director
Woo-Sung Kee 64 2014 Co-CEO & Internal Director
Jae-sik Lee - 2022 Independent Director
Young-hyeh Ko - 2022 Independent Director
Keun-young Kim - 2022 Independent Director
Byung-oh Kwon - - Director
Dae-hyun Yoo - 2022 Independent Director
Soon-Woo Lee 75 2022 Independent Director
Jongmoon Choi - 2023 Independent Director
Jin-seok Seo - 2021 Co-CEO & Inside Co-Chairman of the Board
Joong Jae Lee - 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

068270 Comments

Write your thoughts about Celltrion Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email